X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (330) 330
Conference Proceeding (77) 77
Publication (15) 15
Book Review (11) 11
Book / eBook (8) 8
Book Chapter (7) 7
Magazine Article (2) 2
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (109) 109
hematology (68) 68
humans (65) 65
oncology (56) 56
female (44) 44
male (44) 44
mechanics (40) 40
adult (33) 33
middle aged (32) 32
physics, fluids & plasmas (32) 32
aged (27) 27
physics (23) 23
chemistry (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
models, molecular (19) 19
aged, 80 and over (17) 17
biochemistry & molecular biology (17) 17
molecular conformation (17) 17
prognosis (17) 17
leukemia, lymphocytic, chronic, b-cell - drug therapy (16) 16
quantitative structure-activity relationship (16) 16
treatment outcome (16) 16
fludarabine (15) 15
medicine & public health (14) 14
rituximab (14) 14
structure-activity relationship (14) 14
chemistry, multidisciplinary (13) 13
chemotherapy (13) 13
neurosciences (13) 13
research (13) 13
thermodynamics (13) 13
biophysics (12) 12
mechanics of the fluids (12) 12
pharmacology & pharmacy (12) 12
alemtuzumab (11) 11
analysis (11) 11
animals (11) 11
cyclophosphamide - administration & dosage (11) 11
engineering sciences (11) 11
flow (11) 11
models, chemical (11) 11
psychology, experimental (11) 11
survival (11) 11
transplantation (11) 11
turbulence (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
cancer (10) 10
chemistry, medicinal (10) 10
chronic lymphocytic leukemia (10) 10
computer science, interdisciplinary applications (10) 10
disease-free survival (10) 10
qsar (10) 10
vidarabine - analogs & derivatives (10) 10
abridged index medicus (9) 9
cll (9) 9
cyclophosphamide (9) 9
drug design (9) 9
fluid dynamics (9) 9
instability (9) 9
leukemia, lymphocytic, chronic, b-cell - mortality (9) 9
retrospective studies (9) 9
vidarabine - administration & dosage (9) 9
adolescent (8) 8
animal anatomy / morphology / histology (8) 8
attention (8) 8
chemical phenomena (8) 8
computer applications in chemistry (8) 8
fluid mechanics (8) 8
fluids mechanics (8) 8
medicine/public health, general (8) 8
models (8) 8
nucleic acid conformation (8) 8
protein conformation (8) 8
psychology (8) 8
young adult (8) 8
attention - physiology (7) 7
brain mapping (7) 7
campath-1h (7) 7
cognitive psychology (7) 7
computer simulation (7) 7
disease progression (7) 7
engineering, mechanical (7) 7
follow-up studies (7) 7
leukemia (7) 7
pharmacy (7) 7
physical chemistry (7) 7
trial (7) 7
velocity (7) 7
alkylation (6) 6
article (6) 6
base sequence (6) 6
biochemistry, general (6) 6
care and treatment (6) 6
chemistry, physical (6) 6
drug therapy (6) 6
dynamics (6) 6
event-related potentials (6) 6
experiments (6) 6
expression (6) 6
immunology (6) 6
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (3) 3
UTL at Downsview - May be requested (3) 3
Robarts - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Physics - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1164 - 1174
Summary Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal... 
Internal Medicine | CYTOKINE-RELEASE | MEDICINE, GENERAL & INTERNAL | PLUS CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | PROGRESSION-FREE SURVIVAL | INITIAL THERAPY | LYMPHOMA | STEM-CELL TRANSPLANTATION | EXPRESSION | III TRIAL | DELETION | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Incidence | Leukopenia - chemically induced | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Severity of Illness Index | Antibodies, Monoclonal, Murine-Derived | Drug Administration Schedule | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Rituximab | Treatment Outcome | Vidarabine - analogs & derivatives | Disease Progression | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Vidarabine - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Chronic lymphocytic leukemia | Cyclophosphamide | Fludarabine | Patient outcomes | Dosage and administration | Research | Drug therapy | Studies | Clinical trials | Mutation | Medical statistics | Epidemiology | Annual meetings | Teaching hospitals | Index Medicus | Abridged Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 697 - 22
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2018, Volume 41, pp. 229 - 229
Conference Proceeding
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 09/2017, Volume 40, pp. 192 - 192
Conference Proceeding
Annals of Hematology, ISSN 0939-5555, 2/2014, Volume 93, Issue 2, pp. 267 - 277
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 09/2018, Volume 138, Issue 9, pp. B2 - B2
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 09/2019, Volume 139, Issue 9, pp. S220 - S220
Journal Article
Blood, ISSN 0006-4971, 02/2006, Volume 107, Issue 3, pp. 885 - 891
Journal Article
Cancer, ISSN 0008-543X, 06/2013, Volume 119, Issue 12, pp. 2258 - 2267
BACKGROUND Scarce systematic trial data have prevented uniform therapeutic guidelines for T-cell prolymphocytic leukemia (T-PLL). A central need in this... 
T‐cell prolymphocytic leukemia | T‐cell leukemia 1 | mature T‐cell leukemia/lymphoma | alemtuzumab, fludarabine, mitoxantrone, and cyclophosphamide chemotherapy | T-cell leukemia 1 | T-cell prolymphocytic leukemia | mature T-cell leukemia/lymphoma | mitoxantrone | and cyclophosphamide chemotherapy | CAMPATH-1H | DIAGNOSIS | PENTOSTATIN | CARDIAC TOXICITY | lymphoma | COMBINATION | TRANSPLANTATION | PHASE-II TRIAL | THERAPY | alemtuzumab | ONCOLOGY | fludarabine | CHRONIC LYMPHOCYTIC-LEUKEMIA | mature T-cell leukemia | MYCOSIS FUNGOIDES/SEZARY-SYNDROME | Proto-Oncogene Proteins - metabolism | Cyclophosphamide - administration & dosage | Mitoxantrone - administration & dosage | Humans | Middle Aged | Vidarabine - adverse effects | Leukemia, Prolymphocytic, T-Cell - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Vidarabine - analogs & derivatives | Alemtuzumab | Remission Induction | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Prolymphocytic, T-Cell - drug therapy | Proto-Oncogene Proteins - analysis | Chromosome Aberrations | Adult | Female | Aged | Leukemia, Prolymphocytic, T-Cell - mortality | Vidarabine - administration & dosage | Chemotherapy, Combination | Research | Lymphocytic leukemia | Drug therapy | Patient outcomes | Methods | Index Medicus | Abridged Index Medicus
Journal Article
Angewandte Chemie International Edition, ISSN 1433-7851, 01/2015, Volume 54, Issue 4, pp. 1316 - 1320
NF 3 and N(NO 2 ) 3 are known compounds, whereas the mixed fluoronitroamines, FN(NO 2 ) 2 and F 2 NNO 2 , have been unknown thus far. One of these, FN(NO 2 ) 2... 
quantum chemical calculations | fluoronitroamines | energetic materials | dinitramide anion | Dinitramide anion | Quantum chemical calculations | Fluoronitroamines | Energetic materials
Journal Article